Skip to main content

Discovery of new 5-substituted-indole-2-carboxamides as dual epidermal growth factor receptor (EGFR)/cyclin dependent kinase-2 (CDK2) inhibitors with potent antiproliferative action

Research Authors
Fatma A. M. Mohamed, Saleha Y. M. Alakilli, Eman Fawzy El Azab, Faris A. M. Baawad, Esraa Ibrahim A. Shaaban, Heba Abu Alrub, Omnia Hendawy, Hesham A. M. Gomaa, Adel G. Bakr, Mostafa H. Abdelrahman, Laurent Trembleau, Anber F. Mohammed and Bahaa G. M. You
Research Date
Research Journal
RSC Medicinal chemistry
Research Publisher
Royal society of chemistry
Research Rank
Medicinal chemistry Q2
Research Vol
14 (4)
Research Website
https://pubs.rsc.org/en/content/articlelanding/2023/md/d3md00038a/unauth
Research Year
2023
Research_Pages
734
Research Abstract

A new series of 5-substituted-3-ethylindole-2-carboxamides 5a–k and 6a–c was designed and synthesised
in an attempt to develop a dual targeted antiproliferative agent. Various spectroscopic methods of analysis
were used to confirm the structures of the new compounds. The antiproliferative effect of compounds
5a–k and 6a–c against four cancer cell lines was investigated. Compounds 5a–k and 6a–c had significant
antiproliferative activity against the four cancer cell lines tested, with mean GI50 values ranging from 37 nM
to 193 nM. The most powerful derivatives were compounds 5g, 5i, and 5j, with GI50 values of 55 nM, 49
nM, and 37 nM, respectively, in comparison to the reference erlotinib, which had a GI50 of 33 nM. The four
most potent compounds, 5c, 5g, 5i, and 5j, were then investigated for their efficacy as EGFR inhibitors, and
the findings showed that the tested compounds inhibited EGFR with IC50 values ranging from 85 nM to
124 nM when compared to the reference erlotinib (IC50 = 80 nM). Moreover, compounds 5c and 5g
inhibited CDK2 with IC50 values of 46 ± 05 nM and 33 ± 04 nM, respectively. The EGFR and CDK2 assays
revealed that compounds 5i and 5j displayed potent antiproliferative activity and can be considered as
potential dual EGFR and CDK2 inhibitors.